DermTech Inc (DMTK)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Why Is DermTech (DMTK) Stock Down 26% Today?
DermTech (NASDAQ: DMTK ) stock is falling on Monday as investors prepare for the molecular diagnostic company's shares to be delisted later this week. DermTech received a notice from the Listing Qualifications Department of the Nasdaq Exchange notifying it of its delisting.
Crude Oil Rises 1%; DermTech Shares Plummet
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 0.1% on Tuesday.
DermTech Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 4,332 | $68,445.6 | $407.21 | -$68,038.39 | -99.41% |
| JM John Malone Amundi | 4,128 | $171,600.96 | $150.67 | -$171,450.29 | -99.91% |
DermTech Inc (DMTK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has DermTech Inc ever had a stock split?
DermTech Inc Profile
| Professional Services Industry | Industrials Sector | Bret Christensen CEO | NASDAQ (CM) Exchange | 24984K105 CUSIP |
| US Country | 206 Employees | - Last Dividend | 30 Aug 2019 Last Split | 10 Aug 2017 IPO Date |
Overview
DermTech, Inc. is a pioneering molecular diagnostic company focused on enhancing the detection and management of melanoma through its innovative non-invasive genomic testing methods. Based in San Diego, California, DermTech is dedicated to advancing the field of dermatology by offering cutting-edge alternatives to traditional biopsy procedures. The company's flagship offering, the DermTech Melanoma Test (DMT), exemplifies this approach by providing a novel method for melanoma detection without the need for invasive skin biopsies. Additionally, DermTech engages in research services and technology development on a contractual basis for pharmaceutical companies, aiding in clinical trials and the advancement of dermatologic treatments. Through its development of gene expression assays and custom gene assays, DermTech extends its impact to the broader dermatological drug development industry, working tirelessly to support pharmaceutical partners in their efforts to innovate and improve patient care.
Products and Services
- DermTech Melanoma Test (DMT)
The DermTech Melanoma Test represents a breakthrough in melanoma detection, offering a non-invasive alternative to traditional skin biopsies. By analyzing skin samples for genetic markers associated with melanoma, DMT provides a more comfortable and less intimidating experience for patients, facilitating early detection and potentially improving treatment outcomes.
- DermTech Smart Sticker
Alongside the DMT, DermTech's Smart Sticker technology revolutionizes the collection of skin samples. This product allows for the non-invasive collection of skin cells, eliminating the need for a scalpel biopsy of suspicious lesions. By simplifying the sample collection process, the Smart Sticker enhances patient comfort and compliance, further advancing DermTech's mission to improve dermatological diagnostic practices.
- Research Services and Technology Platform
DermTech offers its proprietary technology and research services on a contract basis to pharmaceutical companies. These services support clinical trials and the development of new dermatological treatments. By providing access to its innovative technology platform, DermTech plays a crucial role in enabling advancements in skincare and treatment efficacy.
- Gene Expression Assays for Dermatological Conditions
The company is also at the forefront of developing gene expression assays tailored to various skin conditions, including psoriasis, atopic dermatitis, and skin aging. These assays are invaluable to pharmaceutical companies developing drug treatments in dermatology, offering insights that facilitate the creation of targeted and effective therapies.
- Custom Gene Assays
In addition to its existing assays, DermTech provides the development of custom gene assays. These are designed to meet the specific research needs of pharmaceutical partners, enabling the precise evaluation of therapeutic efficacy and mechanistic insights for novel dermatological treatments.
